CD276 (CD276 Molecule)

Notably, knockdown of B7H3 in gastric cancer cells significantly inhibited both the expression and nuclear localization of HIF-1α, whereas overexpression of B7H3 markedly promoted HIF-1α expression. In conclusion, the combination of B7H3 and HIF-1α may serve as a novel prognostic biomarker for gastric cancer and also holds potential as a therapeutic target for its treatment.

The Fc-optimized anti-CD276 antibody 8H8_SDIE effectively enhanced NK cell reactivity against CD276-positive CRC cells and induced tumor cell lysis in vitro. These findings suggest that 8H8_SDIE holds potential as a novel immunotherapeutic candidate for CRC, particularly for patients with microsatellite-stable disease, and warrants further evaluation in advanced preclinical and future clinical studies.

Given the high profile of B7-H3 as a therapeutic target for human cancers, our work emphasizes that murine B7-H3 studies using the MJ18 antibody should be interpreted with caution. Finally, we hope that our study will motivate the scientific community to establish much-needed validated research tools to study B7-H3 biology in mouse models.

P1/2, N=820, Recruiting, CSPC Megalith Biopharmaceutical Co.,Ltd.

Our work uncovers the plasticity of PDAC tumor cell states and interactions with the TME that are modified during chemotherapy of unresectable advanced PDAC and pinpoints CD276/B7-H3 as a critical regulator and a promising therapeutic target for overcoming chemotherapy resistance.

This study presents an injectable pH/ROS-dual-responsive hydrogel co-loaded with enoblituzumab (B7-H3 blocker) and Cl-amidine (NETs suppressor)...The hydrogel exhibits excellent biocompatibility without systemic toxicity. This TME-responsive combination strategy offers a promising approach to enhance immunotherapy efficacy and overcome immune resistance in OSCC.

A partial answer to this question is provided through the careful consideration of the available data generated by various clinical trials. The contribution of mass spectrometry-based proteomics to this area of research is highlighted.

P1, N=48, Recruiting, Stanford University | Trial completion date: Dec 2025 --> Jul 2026 | Trial primary completion date: Dec 2025 --> Jul 2026

It reviewed adverse events from novel immunotherapies alone or combined with PD-1/PD-L1/CTLA-4 inhibitors, targeted agents, or chemotherapy. These findings have important clinical implications.

Tonsil tissue was established as a reliable quality control material to ensure assay consistency and reproducibility. The rabbit monoclonal antibody 36H7 exhibits excellent specificity, stability and board applicability across analytical platforams, meeting key requirments for clinical diagnostic development targeting B7-H3 in glioma.